Costs and Spillover Effects of Private Insurers' Coverage of Hepatitis C Treatment
Expanding private-payer coverage of hepatitis C treatment may yield significant long-term cost savings for private payers, reduced costs to Medicare, and increased social value.
Read More
Value of Expanding HCV Screening and Treatment Policies in the United States
Expanding screening for hepatitis C virus infection may generate substantial benefits for patients and society, but only when paired with expanded treatment policies.